Drug Neurology

Leqembi

Payments companies reported to CMS as associated with Leqembi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$8.6Massociated payments (2023-2025)
17,599clinicians with associated payments
4companies reporting

By year

2023 $1.6M
2024 $4.0M
2025 $3.1M

Payments reported as associated with Leqembi, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $5.2M
Behavioral Neurology & Neuropsychiatry $551K
Psychiatry $548K
Family $290K
Neurology With Special Qualifications In Child Neurology $274K
Family Medicine $231K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Leqembi

These are the largest totals companies reported as associated with Leqembi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Daniel Weintraub Philadelphia, PA Psychiatry $296,660.34
John Hemphill Savannah, GA Neurology With Special Qualifications In Child Neurology $266,617.59
John Bertelson Austin, TX Behavioral Neurology & Neuropsychiatry $243,963.68
Paul Schulz Houston, TX Behavioral Neurology & Neuropsychiatry $242,085.33
Armen Moughamian San Francisco, CA Neurology (Psychiatry & Neurology) $209,980.53
Wendell Helveston Jackson, MS Neurology (Psychiatry & Neurology) $204,354.56
Adam Wolff Denver, CO Neurology (Psychiatry & Neurology) $185,235.82
David Weisman Abington, PA Neurology (Psychiatry & Neurology) $168,412.55
Anitha Rao Mishawaka, IN Neurology (Psychiatry & Neurology) $162,962.26
Justin Moon Denver, CO Neurology (Psychiatry & Neurology) $161,224.50

Prescribed Leqembi?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.